{"id":936741,"date":"2026-02-12T19:36:45","date_gmt":"2026-02-13T00:36:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2025-results-within-guidance\/"},"modified":"2026-02-12T19:36:45","modified_gmt":"2026-02-13T00:36:45","slug":"nu-skin-enterprises-reports-fourth-quarter-and-full-year-2025-results-within-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nu-skin-enterprises-reports-fourth-quarter-and-full-year-2025-results-within-guidance\/","title":{"rendered":"Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance"},"content":{"rendered":"

<\/p>\n

Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results Within Guidance<\/b><\/p>\n

Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year\u2019s end<\/b><\/i><\/p>\n

PROVO, Utah–(BUSINESS WIRE<\/a>)–
\nNu Skin Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025.<\/p>\n

Executive Summary
\n
<\/b>Q4 2025 vs. Prior-year Quarter<\/b><\/p>\n\n\n\n\n\n\n
\n

Revenue<\/b><\/p>\n<\/td>\n

\n

\n$370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue<\/p>\n

    \n
  • \n(0.2)% FX impact or $(0.8) million<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

Earnings Per Share (EPS)<\/b><\/p>\n<\/td>\n

\n

\n$0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges<\/p>\n<\/td>\n<\/tr>\n

\n

Customers<\/b><\/p>\n<\/td>\n

\n

\n748,796; (10)%<\/p>\n<\/td>\n<\/tr>\n

\n

Paid Affiliates<\/b><\/p>\n<\/td>\n

\n

\n129,311; (11)%<\/p>\n<\/td>\n<\/tr>\n

\n

Sales Leaders<\/b><\/p>\n<\/td>\n

\n

\n30,045; (19)%<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Executive Summary
\n
<\/b>2025 vs. 2024<\/b><\/p>\n\n\n\n
\n

Revenue:<\/b><\/p>\n<\/td>\n

\n

\n$1.49 billion; (14.3)% or (10.7%) excluding Mavely 2024 revenue<\/p>\n

    \n
  • \n(0.8)% FX impact or $(13.4) million<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

Earnings Per Share (EPS):<\/b><\/p>\n<\/td>\n

\n

\n$3.18 or $1.27 excluding Mavely gain and other charges compared to $(2.95) or $0.84 excluding restructuring and other charges<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u201cWe are pleased to achieve fourth quarter results within our guidance range for both revenue and earnings per share,” said Ryan Napierski, Nu Skin president and CEO. \u201cThis past year was a pivotal year as we furthered our transformation toward becoming the world\u2019s leading intelligent beauty and wellness platform and laid the groundwork for our 2026 growth initiatives. Looking ahead, we continue to build sales leader alignment in the first half of the year around the global launch of Prysm iO, positioning us for a return to year-over-year revenue growth by year\u2019s end.<\/p>\n

\n\u201cWe are now placing Prysm iO intelligent wellness devices into the hands of sales leaders around the world ahead of our consumer launch in the second half of the year. More than 20,000 devices are already in the hands of our sales leaders generating more than 700,000 scans. As we gain greater adoption and more individuals are scanning and receiving their personalized product recommendations, we anticipate this will drive growth in subscriptions leading to greater customer lifetime value. We have also begun pre-market activities in India, setting the operational foundation and infrastructure ahead of a full market opening anticipated in the back half of the year. Overall, we are encouraged by the progress we are making and believe these two initiatives give us the greatest opportunity for sustainable, long-term growth and increased shareholder value.\u201d<\/p>\n

Q4 2025 Year-over-year Operating Results<\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n
\n

Revenue<\/b><\/p>\n<\/td>\n

\n

\n$370.3 million compared to $445.6 million or $413.3 million excluding Mavely 2024 revenue<\/p>\n

    \n
  • \n(0.2)% FX impact or $(0.8) million<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

Gross Margin<\/b><\/p>\n<\/td>\n

\n

\n70.7% compared to 62.7% or 71.4% excluding inventory write-off<\/p>\n

    \n
  • \nNu Skin business was 77.6% compared to 67.5% or 76.6% excluding inventory write-off<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

Selling Expenses<\/b><\/p>\n<\/td>\n

\n

\n35.5% compared to 37.1%<\/p>\n

    \n
  • \nNu Skin business was 40.8% compared to 40.3%<\/p>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n

G&A Expenses<\/b><\/p>\n<\/td>\n

\n

\n29.0% compared to 27.1%<\/p>\n<\/td>\n<\/tr>\n

\n

Operating Margin<\/b><\/p>\n<\/td>\n

\n

\n6.3% compared to (11.9)% or 7.7% excluding restructuring and other charges<\/p>\n<\/td>\n<\/tr>\n

\n

Interest Expense<\/b><\/p>\n<\/td>\n

\n

\n$4.0 million compared to $5.9 million<\/p>\n<\/td>\n<\/tr>\n

\n

Other Income (Expense)<\/b><\/p>\n<\/td>\n

\n

\n$(1.1) million compared to $1.1 million<\/p>\n<\/td>\n<\/tr>\n

\n

Income Tax Rate<\/b><\/p>\n<\/td>\n

\n

\n20.3% compared to 37.5% or 36.6% excluding restructuring and other charges<\/p>\n<\/td>\n<\/tr>\n

\n

EPS<\/b><\/p>\n<\/td>\n

\n

\n$0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Stockholder Value<\/b><\/p>\n\n\n\n
\n

Dividend Payments<\/b><\/p>\n<\/td>\n

\n

\n$2.9 million<\/p>\n<\/td>\n<\/tr>\n

\n

Stock Repurchases<\/b><\/p>\n<\/td>\n

\n

\n$10.0 million<\/p>\n